Theory Paper IIIDrNB Cardiology – Theory Notes

BIOMARKERS IN HEART FAILURE: THE 2026 UPDATE

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ITHE “GOLD STANDARD” PEPTIDES (BNP & NT-proBNP)

  • NT-proBNP in the ARNI Era: Preferred over BNP for longitudinal monitoring in patients receiving Sacubitril/Valsartan (ARNI) because NT-proBNP is not a substrate of neprilysin, whereas BNP degradation is inhibited by sacubitril, causing an expected pharmacological rise in BNP during early treatment.
  • Prognostic Power at Discharge: Pre-discharge NT-proBNP concentration (and a greater than 30 percent reduction from admission) is one of the strongest independent predictors of 30-day heart failure readmission and mortality during the post-discharge vulnerable phase.
  • The Obesity Caveat: Circulating BNP and NT-proBNP concentrations are 30 to 50 percent lower in obese patients (BMI 30 kg/m2 or greater) due to increased adipose NPR-C clearance receptor expression and suppressed myocardial synthesis; diagnostic rule-out thresholds should be lowered by approximately 50 percent (e.g., BNP less than 50 pg/mL).

IIGROWTH DIFFERENTIATION FACTOR-15 (GDF-15)

APathophysiology

  • Cellular Origin: A stress-responsive member of the Transforming Growth Factor-beta (TGF-beta) cytokine superfamily expressed across multiple organs.
  • Pathophysiological Signal: Unlike natriuretic peptides (which reflect biomechanical myocardial wall stretch), GDF-15 integrates systemic oxidative stress, inflammation, tissue hypoxia, and cellular senescence.

BClinical Status

  • Prognostic Utility: GDF-15 is a powerful independent predictor of all-cause mortality and heart failure hospitalization across both HFrEF and HFpEF.
  • Major Bleeding Risk: Elevated GDF-15 strongly predicts major bleeding in patients receiving oral anticoagulation or dual antiplatelet therapy, and is incorporated into the validated ABC-Bleeding Risk Score in atrial fibrillation.

IIIMID-REGIONAL PRO-ADRENOMEDULLIN (MR-proADM)

APathophysiology

  • Endothelial Barrier Marker: Adrenomedullin (ADM) is a potent vasodilator peptide synthesized by vascular endothelial and smooth muscle cells to stabilize endothelial barrier integrity and prevent interstitial edema; MR-proADM is its stable, stoichiometric mid-regional precursor fragment.
  • Pathophysiological Signal: Reflects systemic and pulmonary microvascular endothelial dysfunction, capillary leak, and tissue congestion.

BClinical Status

  • Short-Term Mortality Prediction: In the BACH (Biomarkers in Acute Heart Failure) Trial, MR-proADM was superior to both BNP and NT-proBNP for predicting short-term (14- to 90-day) all-cause mortality in patients presenting to the emergency department with acute dyspnea.
  • Residual Congestion Phenotyping: Elevated MR-proADM (alongside biologically active adrenomedullin, bio-ADM) identifies persistent systemic tissue congestion and predicts early post-discharge readmission.

IVFIBROSIS AND CONGESTION BIOMARKERS

  • Soluble ST2 (sST2): Circulating decoy receptor for Interleukin-33 (IL-33) that blocks cardioprotective IL-33/ST2L signaling and promotes myocardial hypertrophy and fibrosis (ACC/AHA Class IIb for additive risk stratification). Because sST2 has low biological variability and is largely unaffected by age, BMI, atrial fibrillation, or renal function, it is well suited for serial prognostic monitoring (threshold less than 35 ng/mL).
  • Galectin-3: Beta-galactoside-binding lectin secreted by activated macrophages that drives cardiac fibroblast proliferation and collagen synthesis (ACC/AHA Class IIb); unlike sST2, Galectin-3 concentrations are confounded by reduced eGFR.
  • Carbohydrate Antigen 125 (CA-125 / MUC16): Glycoprotein synthesized by mesothelial cells of the pleura, pericardium, and peritoneum in response to hydrostatic pressure and inflammatory cytokines; serves as a reliable biomarker of right-sided heart failure, systemic venous congestion, and serosal effusions (ascites/pleural effusion), and guided diuretic therapy in the CHANCE-HF trial.
Biomarker Primary Biological Pathway Confounded by CKD / eGFR? Confounded by Obesity? Key Clinical / Trial Role
NT-proBNP Myocardial wall stretch Yes (markedly elevated in CKD) Yes (lowered by 30–50%) Class I diagnosis & prognosis; safe in ARNI (PARADIGM-HF, STRONG-HF)
sST2 Biomechanical strain, inflammation, & fibrosis (IL-33 decoy) No (independent of eGFR) No Serial acute/chronic HF prognostication (cut-off <35 ng/mL)
Galectin-3 Macrophage activation & collagen fibrosis Yes (elevated in CKD) No Identifies fibrotic remodeling phenotype
MR-proADM Endothelial barrier stress & capillary leak Moderately No Superior to NPs for 30- to 90-day mortality in acute HF (BACH Trial)
CA-125 Serosal mesothelial stretch & venous congestion No No Quantifies right heart failure / serosal congestion (CHANCE-HF)

VLANDMARK TRIALS AND EVIDENCE

  • PARADIGM-HF (2014) and PIONEER-HF (2019): Demonstrated that Sacubitril/Valsartan transiently increases BNP while significantly lowering NT-proBNP, establishing NT-proBNP as the preferred natriuretic peptide for monitoring patients on ARNI therapy.
  • BACH Trial (2010) and GREAT Network: Proved that MR-proADM outperforms BNP and NT-proBNP for 90-day mortality prediction in acute heart failure.
  • BIOSTAT-CHF Study (2017): Demonstrated that multi-marker profiling incorporating NT-proBNP, GDF-15, sST2, FGF-23, and CA-125 improves risk prediction for mortality and rehospitalization in suboptimally treated heart failure patients.
  • STRONG-HF Trial (2022): Validated serial NT-proBNP monitoring as a safety gatekeeper during rapid up-titration of GDMT to full doses within 2 weeks of discharge (with close follow-up over 6 weeks) after an acute heart failure admission (withholding beta-blocker up-titration if NT-proBNP rose by more than 10 percent above pre-discharge levels and increasing diuretics).

VICLINICAL LIMITATIONS AND DIAGNOSTIC PITFALLS

  • Renal Dysfunction (CKD): Both NT-proBNP and GDF-15 are cleared partially by renal filtration and accumulate as eGFR declines (below 60 mL/min/1.73 m2), requiring higher diagnostic cut-offs.
  • Age-Adjusted Acute HF Rule-In Cut-offs (ICON Study / ESC Guidelines): To account for age-related increases in NT-proBNP, acute heart failure rule-in thresholds are age-stratified (greater than 450 pg/mL for age under 50 years; greater than 900 pg/mL for age 50 to 75 years; and greater than 1,800 pg/mL for age over 75 years), while less than 300 pg/mL rules out acute HF across all ages.

VIIPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

  • Assay Availability and Cost: While NT-proBNP and hs-cTn are widely available across Indian cities, novel biomarkers such as sST2, GDF-15, and MR-proADM remain largely restricted to tertiary referral centers; in resource-limited settings, CA-125 is an inexpensive, widely available assay that independent studies support for tracking right-sided congestion.
  • Comorbid CKD and Anemia Confounding: Because Indian heart failure patients present at a younger age with a high prevalence of diabetic kidney disease and nutritional anemia (both of which elevate baseline NT-proBNP independent of filling pressures), integrating sST2 or CA-125 with clinical and VExUS ultrasound assessment prevents inappropriate over-diuresis.

Key references

  • McDonagh TA, Metra M, Adamo M, et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (and 2023 Focused Update), European Heart Journal, 2021/2023.
  • Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, Circulation, 2022.
  • Maisel A, Mueller C, Nowak R, et al. (BACH Investigators): Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial, Journal of the American College of Cardiology, 2010.
  • Mebazaa A, Davison B, Chioncel O, et al. (STRONG-HF Investigators): Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial, The Lancet, 2022.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.